Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Non Operating Income (2018 - 2025)

Northwest Biotherapeutics' Non Operating Income history spans 8 years, with the latest figure at $18.1 million for Q4 2025.

  • Quarterly results put Non Operating Income at $18.1 million for Q4 2025, up 286.13% from a year ago — trailing twelve months through Dec 2025 was $3.0 million (up 117.13% YoY), and the annual figure for FY2025 was $3.0 million, up 117.13%.
  • Non Operating Income for Q4 2025 was $18.1 million at Northwest Biotherapeutics, up from -$12.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $144.0 million in Q4 2021 to a low of -$17.2 million in Q3 2022.
  • The 5-year median for Non Operating Income is -$1.4 million (2022), against an average of $8.6 million.
  • The sharpest move saw Non Operating Income plummeted 934.68% in 2024, then surged 286.13% in 2025.
  • Year by year, Non Operating Income stood at $144.0 million in 2021, then crashed by 107.03% to -$10.1 million in 2022, then skyrocketed by 111.51% to $1.2 million in 2023, then plummeted by 934.68% to -$9.7 million in 2024, then surged by 286.13% to $18.1 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at $18.1 million, -$12.5 million, and -$599000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.